Goldman Sachs Future Health Care Equity ETF
Goldman Sachs Future Health Care Equity ETF reported 45 holdings worth US$20.1M as of May 31, 2026 (Form N-PORT)
As of May 31, 2026 · Filed Jul 24, 2026
Goldman Sachs Future Health Care Equity ETF reported 45 holdings worth US$20.1M as of May 31, 2026. Largest: Eli Lilly And Company, Johnson & Johnson and Merck & Company, Inc. Filed Jul 24, 2026 (Form N-PORT).
- Holdings
- 45
- Value as reported
- US$20.1M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Eli Lilly And Company | 2,417 | US$2.67M | 13.3% |
| Johnson & Johnson | 7,204 | US$1.62M | 8.1% |
| Merck & Company, Inc. | 10,073 | US$1.2M | 5.9% |
| Guardant Health, Inc. | 8,286 | US$1.07M | 5.3% |
| Astrazeneca Plc | 5,234 | US$974K | 4.8% |
| Thermo Fisher Scientific Inc | 1,847 | US$910K | 4.5% |
| Argenx Se | 979 | US$818K | 4.1% |
| Intuitive Surgical, Inc. | 1,849 | US$785K | 3.9% |
| Boston Scientific Corporation | 15,740 | US$760K | 3.8% |
| Hoya Corporation | 4,173 | US$710K | 3.5% |
| Edwards Lifesciences Corporation | 6,939 | US$600K | 3.0% |
| Lonza Group Ag | 879 | US$563K | 2.8% |
| Dexcom, Inc. | 7,621 | US$562K | 2.8% |
| Agilent Technologies, Inc. | 4,105 | US$556K | 2.8% |
| Roivant Sciences Ltd. | 16,036 | US$481K | 2.4% |
| Cencora, Inc. | 1,750 | US$471K | 2.3% |
| Apogee Therapeutics, Inc. | 4,823 | US$396K | 2.0% |
| Royalty Pharma Plc | 6,370 | US$355K | 1.8% |
| Penumbra, Inc. | 1,015 | US$323K | 1.6% |
| Mettler-toledo International, Inc. | 271 | US$320K | 1.6% |
| Vertex Pharmaceuticals Incorporated | 667 | US$299K | 1.5% |
| Cytokinetics, Incorporated | 3,663 | US$281K | 1.4% |
| Ionis Pharmaceuticals, Inc. | 3,614 | US$276K | 1.4% |
| Xenon Pharmaceuticals Inc. | 4,977 | US$272K | 1.4% |
| Unitedhealth Group Incorporated | 715 | US$272K | 1.4% |
| Repligen Corporation | 2,038 | US$253K | 1.3% |
| Insmed Incorporated | 2,081 | US$222K | 1.1% |
| Galderma Group Ag | 1,034 | US$220K | 1.1% |
| Madrigal Pharmaceuticals, Inc. | 430 | US$214K | 1.1% |
| Revolution Medicines, Inc. | 1,069 | US$168K | 0.84% |
| Cg Oncology, Inc. | 2,432 | US$151K | 0.75% |
| Bridgebio Pharma, Inc. | 2,214 | US$147K | 0.73% |
| Quest Diagnostics Incorporated | 741 | US$144K | 0.72% |
| Rhythm Pharmaceuticals, Inc. | 1,538 | US$136K | 0.68% |
| Alkermes Plc | 2,703 | US$114K | 0.57% |
| Sartorius Stedim Biotech Sa | 533 | US$111K | 0.55% |
| Praxis Precision Medicines, Inc. | 316 | US$111K | 0.55% |
| Definium Therapeutics, Inc. | 4,214 | US$102K | 0.51% |
| Spyre Therapeutics, Inc. | 960 | US$70,560 | 0.35% |
| Insulet Corporation | 398 | US$57,686 | 0.29% |
| Genedx Holdings Corp. | 0 | US$0 | 0.00% |
| Ultragenyx Pharmaceutical Inc. | 0 | US$0 | 0.00% |
| Qiagen N.v. | 0 | US$0 | 0.00% |
| Natera, Inc. | 0 | US$0 | 0.00% |
| Abbott Laboratories | 0 | US$0 | 0.00% |
Source
View original at SEC
Related